Artiva Biotherapeutics (ARTV) Q4 2025 earnings summary

Executive summary

• Advanced AlloNK program, prioritizing refractory rheumatoid arthritis (RA) as lead indication and enrolling patients in community settings.

• Received FDA Fast Track designation for AlloNK in refractory RA and established strong outpatient feasibility and safety profile.

• Strengthened executive and board leadership with expertise in immunology, commercial, and financial strategy.

Financial highlights

• Cash, cash equivalents, and investments totaled $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027.

• Research and development expenses were $69.5 million for 2025, up from $50.3 million in 2024.

• General and administrative expenses were $20.3 million for 2025, compared to $17.2 million in 2024.

• Net loss was $83.9 million for 2025, compared to $65.4 million in 2024.

• License and development support revenue was zero for 2025, down from $0.3 million in 2024.

Outlook and guidance

• Initial clinical response data for AlloNK in refractory RA expected in the first half of 2026 from at least 15 patients.

• Planned FDA interaction in the first half of 2026 to discuss potential pivotal trial design for AlloNK in refractory RA.

• Cash runway expected to fund operations into Q2 2027.